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Abstract
Background: Lassa fever is a rodent-borne zoonosis that clinically manifests as an acute hemorrhagic fever. It is treated 
using ribavarin. Surviving Lassa fever without receiving the antiviral drug ribavarin is rare. Only few cases have been docu-
mented to date.
Case Presentation: We report a case of  a 59-year old female with fever who was initially thought to have acute pyelonephri-
tis and sepsis syndrome with background malaria. Further changes in her clinical state and laboratory tests led to a suspicion 
of  Lassa fever. However at the time her laboratory confirmatory test for Lassa fever returned, her clinical state had improved 
and she made full recovery without receiving ribavarin. Her close contacts showed no evidence of  Lassa virus infection.
Conclusion: This report adds to the literature on the natural history of  Lassa fever; and that individuals may survive Lassa 
fever with conservative management of  symptoms of  the disease and its complications.
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Introduction
Lassa fever is a zoonotic disease that commonly mani-
fests as an acute viral hemorrhagic fever. It was first 
described in northeastern Nigeria in 1969, and it is 
endemic in West Africa1. The animal reservoir of  the 
Lassa fever virus is a rat, Mastomys natalensis. Trans-
mission occurs through direct exposure to the excreta/
blood of  infected rats, or from person to person via 
body fluids. The incubation period ranges between 7 to 
18 days2. In endemic areas, an estimated 300,000 – 500, 
000 cases and 5000 to 10,000 deaths occur annually3. 
About 80% of  persons infected with the Lassa virus 
are asymptomatic; but in the remaining 20%, the illness 
manifests as a febrile illness of  variable severity associ-
ated with multiple organ dysfunctions with or without 
hemorrhage1-3.
Since the discovery of  Lassa fever, Nigeria has experi-
enced several epidemics; one of  the most recent affect-
ed 19 States of  the federation includes Ebonyi State3, 
4. Majority of  the earliest cases of  Lassa fever died5. 
Only one of  these early laboratory confirmed case was 
documented to have survived with supportive therapy 
alone1. Early attempts at treating Lassa fever involved 
total isolation and supportive therapy with or with-
out the use of  the convalescent serum or antibody5,6. 
Presently, Lassa fever management involves the use of  
ribavarin, supportive therapy, and simple barrier nurs-
ing usually in a specific ward dedicated for the disease6. 
Treatment with intravenous ribavarin is particularly use-
ful in decreasing Lassa fever mortality – its administra-
tion within the first 6 days of  illness has been shown to 
decrease the mortality of  severe Lassa fever from 55% 
to 5%6.
We recently encountered an individual with Lassa fever 
that survived without receiving ribavarin. At Lassa fever 
suspicion, the patient’s clinical management was based 
on the World Health Organisation (WHO) / Centers 
for Disease Control (CDC) guidelines7. However, at the 
time her laboratory confirmatory test for Lassa fever 
returned, her symptoms had markedly resolved; she 
was not given ribavarin but monitored closely and dis-
charged.
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Case presentation
The patient was a 59 year old female farmer who hails 
and resides in Ebonyi State, Nigeria. She was admitted 
with a one week history of  fever, shaking chills, severe 
headaches, anorexia and body weakness. On the day of  
presentation, she had two episodes of  vomiting but no 
hematemesis. She admitted to taking meals of  game 
that often included rat meat. Before presentation, she 
visited a district hospital where she was treated with in-
travenous quinine and chloramphenicol and at presen-
tation she was on oral antimalarials (artemether-lume-
fantrine) and ciprofloxacin without improvement. She 
was a known hypertensive diagnosed three years ago; 
and had been compliant with her anti-hypertensives.
On examination, she had a temperature (T) of  39.10C 
and was moderately pale; pulse rate was 78 beats per 
minute and blood pressure 130/80 mmHg. Her respira-
tory rate was 32 cycles per minute; other components of  
the chest and neurologic examinations were unremark-
able. On abdominal examination, she had hepatomeg-
ally and bilateral loin tenderness. A diagnosis of  acute 
pyelonephritis and sepsis syndrome with background 
poorly treated malaria was made. Blood samples were 
collected for blood culture, complete blood count and 
film for malaria parasites, serum electrolytes, urea and 
creatinine, hepatic enzymes, urinalysis and urine mi-
croscopy, culture and sensitivity. She continued her oral 
antimalarials, antibiotic, and antihypertensive as well as 
intravenous fluid infusion. Her urinalysis showed mas-
sive hematuria (+++), proteinuria (++), glucose (+), 
bacteruria (++) and granular cast (++). The blood ex-
amination showed malaria parasitaemia (+), leucopenia 
with relative lymphocytosis (Table 1).
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Table 1: Complete blood count changes in an individual with confirmed Lassa fever 
Variables Day 1 Day 4 Day 8 Day 11 Day 15 After 2 
weeks 
Reference value 
Hemoglobin 12 8.3 9 9.3 9.6 10 12 – 16 g/dl 
WBC count 1.7 4.2 4.4 6.0 6.2 5.2 4 – 11 x 109 cells / liter 
     Neutrophils 48 16 13 30 50 43 40 – 70% 
     Lymphocytes 52 84 84 70 50 55 20 – 40% 
     Eosinophils 0 02 01 0 0 2 1 – 6% 
     Monocytes 0 0 02 0 0 0 2 – 10% 
     Basophils 0 0 0 0 0 0 0 – 1% 
Thrombocytes 80 62 102 130 149 - 150 – 400 x 109 / liter 
Malaria parasite (+) (+) (-) (-) (-) - Positive(+) / negative (-) 
Reticulocyte count - 0.6 1.3 1.4 - - 0.2 – 2.0  
Also, her serum hepatic enzymes were elevated (aspar-
tate aminotransferase, 101 IU per liter; alanine ami-
notransferase, 68 IU per liter). However, blood culture, 
serum bilirubin, urea and creatinine were unremark-
able.
Three days later, the fever persisted (T, 390C), and she 
developed noisy breathing. On examination, she had 
coarse crackles at her lung bases, and rhonchi all over 
her lung zones. The oral antibiotics were stopped and 
she was commenced on intravenous amoxicillin-clavu-
lanic acid, and later ceftazidime, and intravenous artesu-
nate. On the 8th day of  admission, she still had fever 
(T, 38.20C), but no longer had loin pains and headaches. 
A repeat CBC showed anaemia, neutropenia, massive 
lymphocytosis and thrombocytopenia (Table 1); how-
ever, malaria parasites were absent. The Lassa fever 
management team was invited. Following review, a di-
agnosis of  suspected Lassa fever was made. The patient 
blood sample was sent for Lassa virus-specific reverse 
transcriptase polymerase chain reaction (RT-PCR) us-
ing previously described methods8.
Over the next three days, she had a gradual fall in tem-
perature. On the 11th day of  admission, she complained 
of  numbness on her feet, and her temperature had fall-
en to 37.40C. The noisy breathing and abdominal pain 
has resolved. On that day, her Lassa virus-specific RT-
PCR test results returned and the diagnosis of  Lassa 
fever was confirmed. Due to her improving clinical 
state, intravenous ribavarin was not commenced; but, 
her temperature was monitored closely. The intrave-
nous antibiotics were continued with oral vitamin B-
complex. The numbness resolved on the 14th day of  
admission. Two repeat CBC done on the 11th and 15th 
day of  admission showed improving indices (Table 1). 
The patient was discharged on the 18th day of  admis-
sion. On follow-up visits two and four weeks after dis-
charge, she remained well. A CBC done two weeks after 
discharge showed further improving hematologic indi-
ces (Table 1). Presently, she has a monthly follow-up 
appointment.
Sixteen individuals found to be high-risk contacts of  
the patient were screened but showed no evidence of  
Lassa virus infection.
Discussion
Surviving Lassa fever without antiviral treatment using 
ribavarin is perceived to be rare. Only one individual 
has been documented to have survived without receiv-
ing the anti-viral agent ribavarin1. Others, who had sur-
vived without receiving ribavarin were not confirmed9, 
and if  confirmed, were either given serum of  the Lassa 
fever survivor5, or had scanty information on how they 
were managed2. At presentation, our patient’s signs and 
symptoms were insufficient to consider a differential 
diagnosis of  “suspected Lassa fever”7. But, given that 
she still had malaria parasitaemia and bacteruria, Lassa 
fever suspicion was given less consideration. However, 
the persistence of  severe fever despite receiving vari-
ous antimalarials and antibiotics as well as evidence of  
clearance of  the malaria parasitaemia reignited the sus-
picion of  Lassa fever. The first documented survivor 
of  Lassa fever also received empirical antimalarials and 
antibiotics despite no evidence of  bacteria or plasmodi-
um infection1. It is possible that these agents may have 
some effect on the pathophysiology of  Lassa fever.
At the time of  the confirmation of  Lassa fever, the pa-
tient’s clinical state had substantially improved; hence 
ribavarin was not given to her. Moreover, the patient 
had features that are known adverse effects of  ribavarin; 
anaemia, rigors, nausea and vomiting, abdominal pain, 
fatigue, and headache10, were key symptoms the patient 
presented with. If  ribavarin was administered and her 
clinical state deteriorates, it will be difficult to differenti-
ate between the adverse effects of  ribavarin and wors-
ening of  the Lassa fever. The Lassa virus-specific RT-
PCR used to confirm the diagnosis is the gold standard 
for Lassa fever confirmation. Also, the RT- PCR assay 
currently in use in Nigeria has 100% sensitivity in de-
tecting the local strains of  the Lassa virus11. She had an 
admission AST of  101 I.U per liter, a previous study 
has shown that hospitalized Lassa fever cases with ad-
mission AST ≥ 150 IU per liter have increased mortal-
ity6. Our report suggests that a patient with laboratory 
confirmed Lassa fever with falling temperature, low ad-
mission AST <150 IU per liter and improving clinical 
state may not require treatment with ribavarin.
None of  the individuals classified as a high-risk contact 
of  the patient had evidence of  Lassa virus infection. 
Also, none of  the health workers who participated in the 
management of  the patient were infected. This agrees 
with previous findings that Lassa virus is not as infec-
tious as it is always suspected–previous observations 
have shown that even repeated, often intimate contact 
of  Lassa fever patients described by family members 
often fail to transmit the infection12,13. It was not pos-
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sible to demonstrate other changes in the patient’s bio-
chemical parameters during recovery and discharge due 
to high treatment costs.
Future research needs to be conducted in communities 
with Lassa fever to identify individuals with high circu-
lating immunoglobulin-G antibodies to the Lassa virus 
i.e., those who might have had clinical or subclinical in-
fection and recovered. Identified cases needs to be eval-
uated to determine the factors associated with survival. 
Furthermore, they should be followed in a cohort study 
to determine if  past infection with Lassa virus affects 
the risk of  recurrence, re-infection, or clinical presenta-
tion of  other diseases which manifests with fever.
Conclusion
This report adds to the literature on the natural history 
of  Lassa fever. It suggests that conservative manage-
ment of  symptoms of  the disease and its complications 
may improve survival of  individuals infected with Lassa 
fever. There is need for the development of  reliable 
point of  care tools in order to quickly confirm or rule 
out the diagnosis of  Lassa fever, and other viral hemor-
rhagic fevers once suspected. This is the next challenge 
in tackling Lassa, Ebola, and Marburg hemorrhagic fe-
vers in Africa14.
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